Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

NCT03009045 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Bone and Joint Infection

Interventions

DRUG: Tedizolid

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center